By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agilent Technologies today reported a 32 percent jump in fiscal second-quarter revenues year over year, with its Life Sciences segment seeing a 39 percent spike.

The company reported total revenues of $1.68 billion for the three months ended April 30, up from $1.27 billion a year ago, beating Wall Street expectation of $1.6 billion. Excluding the effects of acquisitions and divestitures, revenues rose 21 percent in the quarter year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.